Alyssa Birt Email

Senior Scientist . AffyImmune Therapeutics

Current Roles

Employees:
33
Revenue:
$2.6M
About
Founded in 2016, AffyImmune is a clinical-stage biotechnology company that optimizes CAR T cells for the treatment of solid tumors using our Tune & Track platform. AIC100, our first product, spares healthy cells through our unique affinity-tuning, enhancing its safety and efficacy. The initial indication for AIC100 is refractory thyroid cancer, which has a very poor prognosis and very few effective therapies. The antigen targeted by AIC100 is also overexpressed in a variety of additional cancers, including stomach, triple negative breast cancer and a number of others.
AffyImmune Therapeutics Address
22 Strathmore Road
Natick, MA
AffyImmune Therapeutics Email

Past Companies

AffyImmune TherapeuticsSenior Scientist
AffyImmune TherapeuticsScientist II
Aleta BiotherapeuticsScientist II

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.